Vimarsana
Biggest News Aggregation in the World

Page 8 - David Mcalpine News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from David Mcalpine. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In David Mcalpine Today - Breaking & Trending Today

Illumina and Pillar Biosciences partner to improve access to personalized cancer treatment options - Vimarsana News

Illumina and Pillar Biosciences partner to improve access to personalized cancer treatment options

/PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, and Pillar Biosciences Inc., the pioneers of...

The Alliance for Genomic Discovery announces founding biopharma members: AbbVie, Amgen, AstraZeneca, Bayer, and Merck - Vimarsana News

The Alliance for Genomic Discovery announces founding biopharma members: AbbVie, Amgen, AstraZeneca, Bayer, and Merck

/PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, in collaboration with Nashville Biosciences, LLC,...

Illumina to Announce Second Quarter 2023 Financial Results on Wednesday, August 9, 2023 - Vimarsana News

Illumina to Announce Second Quarter 2023 Financial Results on Wednesday, August 9, 2023

/PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the second quarter 2023 following the close of market on Wednesday,...

Europe Imposes Maximum Fine on Illumina for Early Grail Acquisition - Vimarsana News

Europe Imposes Maximum Fine on Illumina for Early Grail Acquisition

Illumina must pay a €432 million fine for closing its Grail acquisition before the European Commission finished its inquiry into the tie-up. The penalty is the maximum amount the regulator can impose on a company for breaching European merger rules.

Illumina hit by EU with maximum fine for Grail acquisition - Vimarsana News

Illumina hit by EU with maximum fine for Grail acquisition

BioPharma